Catalyst Pharmaceuticals Company Insiders
| CPRX Stock | USD 15.12 0.39 2.65% |
Catalyst Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Catalyst Pharmaceuticals suggests that vertually all insiders are panicking. Catalyst Pharmaceuticals employs about 167 people. The company is managed by 27 executives with a total tenure of roughly 186 years, averaging almost 6.0 years of service per executive, having 6.19 employees per reported executive.
| Patrick McEnany Chairman Co-Founder, Chairman, CEO and Pres |
| Bernardino Mosquera President Vice President - Clinical Operations |
Catalyst Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-08 | David S Tierney | Disposed 25000 @ 15.68 | View | ||
| 2024-03-27 | Brian Elsbernd | Disposed 25000 @ 16.44 | View | ||
| 2023-12-12 | David S Tierney | Disposed 50000 @ 13.32 | View | ||
| 2023-12-11 | Alicia Grande | Disposed 60000 @ 13.76 | View | ||
| 2023-12-08 | Alicia Grande | Disposed 40000 @ 14.28 | View | ||
| 2023-12-05 | Steve Miller | Disposed 40000 @ 14.24 | View | ||
| 2023-05-15 | Patrick J Mcenany | Disposed 26151 @ 13.23 | View |
Monitoring Catalyst Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Catalyst |
Catalyst Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Catalyst Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Catalyst will maintain a workforce of slightly above 170 employees by May 2024.Catalyst Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.1283 % which means that it generated a profit of $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2075 %, meaning that it created $0.2075 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Asset Turnover is fairly stable compared to the past year.Net Income Applicable To Common Shares is likely to rise to about 100.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 57 M in 2024.
Catalyst Pharmaceuticals Workforce Comparison
Catalyst Pharmaceuticals is rated second in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 617. Catalyst Pharmaceuticals totals roughly 167 in number of employees claiming about 27% of equities under Health Care industry.
Catalyst Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of 0.18 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.92 | 0.7877 |
|
|
Catalyst Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Catalyst Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.0 | 2 | 1 | 50,000 | 25,000 |
| 2024-03-01 | 0.72 | 18 | 25 | 2,159,513 | 916,699 |
| 2023-12-01 | 1.2727 | 42 | 33 | 1,793,705 | 736,846 |
| 2023-09-01 | 1.0 | 1 | 1 | 60,000 | 60,000 |
| 2023-06-01 | 0.6667 | 8 | 12 | 460,000 | 560,093 |
| 2023-03-01 | 0.7353 | 25 | 34 | 485,995 | 623,190 |
| 2022-12-01 | 1.4375 | 46 | 32 | 2,197,627 | 1,551,494 |
| 2022-09-01 | 0.3617 | 17 | 47 | 862,143 | 3,167,169 |
| 2022-06-01 | 0.3 | 3 | 10 | 170,000 | 379,082 |
| 2022-03-01 | 5.3333 | 16 | 3 | 602,500 | 140,000 |
| 2021-12-01 | 2.0833 | 25 | 12 | 1,345,833 | 95,051 |
| 2021-09-01 | 0.4615 | 12 | 26 | 805,000 | 1,616,996 |
| 2021-06-01 | 0.25 | 1 | 4 | 10,000 | 206,264 |
| 2020-12-01 | 1.6154 | 21 | 13 | 1,776,496 | 116,242 |
| 2019-12-01 | 10.0 | 30 | 3 | 2,684,000 | 350,000 |
| 2018-12-01 | 5.8 | 29 | 5 | 1,665,000 | 440,000 |
| 2018-06-01 | 4.5 | 9 | 2 | 570,000 | 50,000 |
| 2018-03-01 | 11.0 | 22 | 2 | 1,355,000 | 33,334 |
| 2017-12-01 | 0.7778 | 7 | 9 | 776,667 | 792,387 |
| 2017-09-01 | 1.0 | 1 | 1 | 20,000 | 50,000 |
| 2017-06-01 | 1.0 | 2 | 2 | 62,500 | 62,500 |
| 2016-12-01 | 1.0 | 1 | 1 | 26,667 | 26,667 |
| 2015-12-01 | 4.125 | 33 | 8 | 1,286,666 | 310,585 |
| 2015-09-01 | 0.8 | 4 | 5 | 146,615 | 163,385 |
| 2015-03-01 | 2.5 | 5 | 2 | 450,804 | 432,343 |
| 2014-12-01 | 1.0 | 12 | 12 | 815,036 | 833,625 |
| 2014-09-01 | 23.0 | 23 | 1 | 1,390,000 | 0.00 |
| 2012-12-01 | 11.0 | 22 | 2 | 6,174,000 | 11,666,667 |
| 2010-09-01 | 4.0 | 4 | 1 | 5,951 | 36,481 |
| 2010-03-01 | 2.5 | 5 | 2 | 42,450 | 26,668 |
| 2009-12-01 | 5.8333 | 35 | 6 | 1,134,100 | 879,610 |
| 2009-06-01 | 1.0 | 1 | 1 | 100.00 | 13,334 |
| 2008-09-01 | 21.0 | 21 | 1 | 22,401 | 415.00 |
| 2008-03-01 | 16.0 | 16 | 1 | 109,967 | 513.00 |
| 2007-06-01 | 4.0 | 4 | 1 | 15,000 | 0.00 |
| 2007-03-01 | 8.0 | 8 | 1 | 50,398 | 0.00 |
Catalyst Pharmaceuticals Notable Stakeholders
A Catalyst Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Catalyst Pharmaceuticals often face trade-offs trying to please all of them. Catalyst Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Catalyst Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard MBA | CEO President | Profile | |
| Patrick McEnany | Co-Founder, Chairman, CEO and Pres | Profile | |
| Bernardino Mosquera | Vice President - Clinical Operations | Profile | |
| Alicia Grande | CFO, Vice President Treasurer | Profile | |
| Douglas Winship | Vice President - Regulatory Operations | Profile | |
| David Caponera | Vice President - Patient Advocacy & Reimbursement | Profile | |
| Michael CPA | Executive CFO | Profile | |
| Steven Miller | COO and Chief Scientific Officer | Profile | |
| David Muth | Chief Commercial Officer and Executive VP | Profile | |
| Donald Denkhaus | Director | Profile | |
| Charles OKeeffe | Lead Independent Director | Profile | |
| David Tierney | Independent Director | Profile | |
| Philip Coelho | Independent Director | Profile | |
| Richard Daly | Interim Chief Commercial Officer, Director and Member of Nominating and Corporate Governance Committee | Profile | |
| Pete Sr | Vice Sales | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Gary MD | Chief Officer | Profile | |
| Jeffrey Carmen | Executive Officer | Profile | |
| Preethi Sundaram | Chief Officer | Profile | |
| Daniel Brennan | Chief Commercial Officer | Profile | |
| Philip Schwartz | Co Sec | Profile | |
| CMA CPA | VP, Officer | Profile | |
| Stanley MD | Senior Discovery | Profile | |
| Gary Ingenito | Chief Medical Officer | Profile | |
| David Connolly | IR Contact Officer | Profile | |
| Brian Elsbernd | Chief Compliance Officer, Chief Legal Officer | Profile | |
| Brian JD | Chief Officer | Profile |
About Catalyst Pharmaceuticals Management Performance
The success or failure of an entity such as Catalyst Pharmaceuticals often depends on how effective the management is. Catalyst Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Catalyst management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Catalyst management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.26 | 0.27 | |
| Return On Capital Employed | 0.22 | 0.23 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.18 | 0.19 |
The data published in Catalyst Pharmaceuticals' official financial statements usually reflect Catalyst Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Catalyst Pharmaceuticals. For example, before you start analyzing numbers published by Catalyst accountants, it's critical to develop an understanding of what Catalyst Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Catalyst Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Catalyst Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Catalyst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalyst Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.
Catalyst Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Catalyst Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Catalyst Pharmaceuticals within its industry.Catalyst Pharmaceuticals Manpower Efficiency
Return on Catalyst Pharmaceuticals Manpower
| Revenue Per Employee | 2.4M | |
| Revenue Per Executive | 14.7M | |
| Net Income Per Employee | 427.6K | |
| Net Income Per Executive | 2.6M | |
| Working Capital Per Employee | 857.9K | |
| Working Capital Per Executive | 5.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.